BridGene Biosciences, Inc.

10:45 AM - 11:00 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
BridGene is a Biotech company founded by Dr. Chao Zhang based on his well recognized research in Chemical Genetics, Covalent Kinase Inhibitor, and Chemical Proteomics. We are blessed with scientific guidance from three world-class Scientific Advisors: Dr. Kevan Shokat, Dr. Arthur Weiss (Both are Member of NAS, NAM, and AAAS) and Dr. Ariel Warshel (Nobel Laureate).

BridGene focuses on the discovery of small-molecule covalent inhibitors for targets in the fields of Oncology, Immunology, and Neurodegenerative Diseases. We have an innovative discovery platform called IMTAC that shares some similarities with Vividion Therapeutics‘s platform, but has some advantages. IMTAC can be used to (i) discover ligands for "unliganded" or "undruggable" targets; (ii) largely reduce the time and cost of lead discovery; (iii) identify additional targets of drugs or clinical candidates; (iv) create a unique ligand-target interaction database to guide small molecule drug design.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
IMTAC Platform
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4